The Prescription for Pharmacoeconomic Analysis (PFPA) is a guide for assessing the value for money of pharmaceuticals in New Zealand.
Version 2.2 of the PFPA, published in August 2015, supports assessment of medical devices, vaccines and medicines under the Factors for Consideration.
The update to version 2.2 took into account feedback received during consultation on our decision-making framework and medical devices activities.
The PFPA provides a detailed guide to the methods PHARMAC uses for health economic analysis of health funding. The preferred method is cost-utility analysis, which informs the “health benefits” and “costs and savings” dimensions of the Factors for Consideration, and can generate information helpful for considering Factors in the “need” and “suitability” dimensions.
Documenting our methodology aims to ensure that economic analyses by and for PHARMAC measure costs, benefits, time preference and uncertainty in a similar fashion; hence enabling comparison between the cost-effectiveness of different interventions and ensuring that the results of analyses are meaningful for decision making. The intended audience for the PFPA is medicine and medical device suppliers, PHARMAC staff, clinicians, and contracted health economists preparing economic analyses for PHARMAC.
For applications to be considered using:
If you want a previous version of the PFPA, contact us at firstname.lastname@example.org.
Version 2.1 can be referred to for analyses intended to be assessed against the Decision Criteria that preceded the Factors for Consideration.
Version 2.2 of the PFPA reflects our expanding role into vaccines and medical devices.
A summary of changes and specific information relating to medical devices and vaccines is in our PFPA Supplement 2: Assessment of Medical Devices and Vaccines.
Cost-Utility Analysis (CUA) Explained provides a simple explanation of general CUA concepts. CUA Explained was also updated in August 2015.
The following general CUA concepts are covered:
- a quick overview of CUA
- assessing clinical evidence for inclusion in a CUA
- assessing benefits and costs
- managing risk in CUA
- the economic model
- the cost per quality-adjusted life year (QALY) result of a CUA
- using the cost per QALY information
- and commonly asked questions and answers regarding CUA
For detailed information on the methods for CUA at PHARMAC, please refer to the Prescription for Pharmacoeconomic Analysis.
The Cost Resource Manual aims to increase consistency in the costs used in economic analyses provided to PHARMAC as part of pharmaceutical funding applications. It provides information on the key costs that PHARMAC regularly uses in cost-utility analyses and budget impact analyses, so that applicants may, if they wish, use the same cost data in their own economic analyses for PHARMAC.
The following key costs are regularly used in PHARMAC CUAs and are covered in this manual:
- pharmaceutical costs (page 2)
- primary care costs (page 4)
- hospital costs (page 5)
- diagnostic imaging and laboratory tests (page 7)
- community care costs (page 8).
Technology Assessment Reports are detailed analyses of new pharmaceuticals. They are used to determine the cost-effectiveness of pharmaceuticals that we are being asked to fund.
We don't publish most of our Technology Assessment Reports, because of commercial sensitivity.
Last updated: 4 February 2016